FDA licenses new hemophilia treatment.
The new treatment, called Xyntha Antihemophilic Factor (Recombinant) Plasma/Albumin Free, is a genetically engineered version of factor VIII, a protein essential for the clotting of blood. Factor VIII, known as an antihemophilic factor, is missing or decreased in patients with hemophilia A.
Xyntha is licensed for the control and prevention of bleeding, which can occur spontaneously or after an accident or injury in patients diagnosed with hemophilia A. Xyntha is also licensed to help prevent surgical bleeding in this patient population.
Xyntha is manufactured using recombinant DNA techniques that enable scientists to create new DNA strands with specific traits, such as the capacity to produce a specific protein.
Xyntha is manufactured by Wyeth Pharmaceuticals Inc., located in Philadelphia.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Industry News|
|Date:||Mar 1, 2008|
|Previous Article:||Genmab to buy Minnesota biotech plant from PDL Biopharma.|
|Next Article:||Mix-ups could be worsened by computerized systems.|